Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL By Ogkologos - December 6, 2024 787 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the STARGLO study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR A radical project: video game design meets cancer research December 1, 2022 When Both Tumour-Infiltrating Lymphocytes and Gene Expression are Available, the Prognostic... January 23, 2023 ESMO Gastrointestinal Cancers Congress 2024 Munich, Germany, 26-29 June June 14, 2024 ACS’s Updated Cervical Cancer Screening Guidelines Explained September 18, 2020 Load more HOT NEWS Nature’s Bounty: Revitalizing the Discovery of New Cancer Drugs from Natural... Cancer in My Community: Working to Expand Access to Clinical Trials... The Potential of AI to Improve Cancer Care is Only Going... EMA Recommends Extension of Indications for Nivolumab to Include First-Line Treatment...
